Daily Clinical Briefing · Educational reading for healthcare professionals
TTM2 and ICECAP separate fever control from the unanswered question of whether hypothermia helps.
A flat cooling-duration response in ICECAP does not show that short hypothermia is better than no cooling.
Cooling a patient to 33°C after cardiac arrest is not the same clinical question as deciding how long cooling should continue. Mixing those questions makes the recent evidence easier to misread.
TTM2 compares 33°C hypothermia with normothermia plus active fever treatment after out-of-hospital cardiac arrest. The normothermia group is not simply left alone: temperature is targeted at 37.5°C and a cooling device is introduced if it reaches 37.8°C. Against that comparator, hypothermia does not improve survival or neurological outcome.
ICECAP asks something different. Patients enter the trial only when the clinical team already intends to use hypothermia and the patient reaches a temperature below 34°C within four hours of arrest. The study then compares different durations of cooling.
That design matters. ICECAP finds a flat duration–response relationship and no outcome advantage from extending cooling to 48 hours. It does not show that six hours of cooling is better than no cooling, because there is no untreated or normothermia comparison group answering that question.
There is also a practical cost to longer treatment. Shivering raises body temperature and requires continued management, while prolonged hypothermia extends the period during which laboratory abnormalities and the logistics of temperature control need attention. ICECAP uses controlled rewarming to 36.5°C followed by continued normothermia until liberation from mechanical ventilation or a maximum of 120 hours.
Outcome reporting needs care as well. ICECAP uses a weighted modified Rankin score in which scores of 4–6 are assigned zero, combining death with poor neurological outcome among survivors. A summary weighted score cannot therefore be read as though it were simply a mortality percentage.
Differences between the trial populations also limit direct comparisons. Bystander cardiopulmonary resuscitation rates, presenting rhythms and early-cooling eligibility differ, so apparent differences in mortality between TTM2 and ICECAP cannot sensibly be attributed to one factor alone.
For practice, the useful distinction is straightforward. Evidence about whether to initiate 33°C hypothermia should be considered separately from evidence about how long to continue it. ICECAP weakens the case for prolonged cooling; it does not establish that short-duration hypothermia is beneficial.
Anticoagulation during PCI for non-ST-elevation acute coronary syndrome requires balancing ischaemia and bleeding, with unfractionated heparin the class 1 option discussed, fondaparinux unsuitable alone during PCI, and historical bivalirudin comparisons complicated by unequal IIb/IIIa inhibitor use.
TTM2 finds no survival or neurological advantage from 33°C hypothermia over normothermia with active fever treatment after cardiac arrest, while ICECAP examines cooling duration and finds no benefit from prolonging hypothermia to 48 hours.
Remethylation disorders can present with neurological, psychiatric, eye or renal disease across the age range; total homocysteine, methionine, methylmalonic acid, vitamin B12, holotranscobalamin and folate help distinguish vitamin deficiency from inherited metabolic disease.
Newborn vitamin K deficiency can cause severe and sometimes intracranial bleeding without warning, while one intramuscular dose provides more reliable protection than repeated oral prophylaxis and requires clear discussion of benefits, historical safety concerns and parental fears.
Delusional misidentification involves fixed beliefs about abnormal familiarity and occurs in psychiatric and neurological disease; new onset in an older adult without a clear trigger should raise concern for neurodegeneration and prompt direct enquiry and caregiver support.
When reviewing post-arrest temperature management, separate the decision to start hypothermia from the decision about its duration. Do not use ICECAP as evidence that short-duration cooling is superior to no cooling. If temperature control is continued, make the rewarming and subsequent normothermia plan explicit.
An intensive care team proposes six hours of hypothermia after cardiac arrest because ICECAP shows no advantage from longer cooling. Does the trial establish that six hours of cooling is better than normothermia?
No. ICECAP compares different cooling durations in patients already selected for hypothermia and cooled below 34°C early. It does not include a normothermia group and therefore cannot establish benefit from initiating hypothermia.
A patient with non-ST-elevation acute coronary syndrome initially receives fondaparinux during conservative management but subsequently deteriorates and requires immediate PCI. Can fondaparinux alone be used as the procedural anticoagulant?
No. Fondaparinux alone carries a catheter-thrombosis risk during PCI and should not be used as the sole procedural anticoagulant.
A two-month-old infant who received no vitamin K prophylaxis presents with seizures and unresponsiveness but has had no previous bleeding. Does the absence of a warning bleed make late vitamin K deficiency bleeding unlikely?
No. Late vitamin K deficiency bleeding can occur without a warning bleed, and intracranial haemorrhage accounts for a substantial proportion of presentations.
Daily Clinical Briefings are prepared using ChatGPT Pro from the show notes and educational output for that day’s episodes. Iain Beardsell then checks the briefing for accuracy.
This describes the current briefing process. Item-specific review dates are shown only where documented. The original podcasts remain the sources; MedPod’s briefing is additional educational material.
Read about MedPod’s editorial approach
Report an error or source concern — please include the article title and link, without patient-identifying information.
.svg)